On January 1, 2024, AlloVir Board Approved Reduction Its Workforce By Approximately 95% Of Current Employee Base To Reduce Costs And Preserve Capital - Filing

1/4/24 5:27:25 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ALVR alert in real time by email

The move follows AlloVir’s announcement on December 22, 2023 that it is discontinuing its three global Phase 3 posoleucel studies. This workforce reduction will take place primarily during the first quarter of 2024 and expects to be substantially completed by April 15, 2024. As a result of these actions, AlloVir expects to incur personnel-related restructuring charges of approximately $13 million in connection with one-time employee termination cash expenditures, including severance and other benefits, which are expected to be substantially incurred in the first quarter of 2024.

Get the next $ALVR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ALVR

Date	Price Target	Rating	Analyst
12/26/2023	$17.00 → $1.00	Buy → Underperform	BofA Securities
12/22/2023		Outperform → Market Perform	Leerink Partners
12/22/2023		Overweight → Underweight	JP Morgan
12/22/2023		Overweight → Neutral	Piper Sandler
8/18/2023	$17.00	Buy	BofA Securities
2/10/2022	$32.00 → $30.00	Outperform	SVB Leerink
1/18/2022	$48.00 → $45.00	Overweight	Morgan Stanley
12/17/2021	$37.00 → $32.00	Outperform	SVB Leerink

More analyst ratings

$ALVR
Leadership Updates

Live Leadership Updates

AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo
3/4/24 5:37:52 PM ET
$ALVR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio
2/28/24 1:06:25 AM ET
$ALVR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer
- Industry veteran brings more than 25 years of global commercial leadership and cell therapy expertise to AlloVir to build out company's commercial strategy and capabilities - AlloVir (NASDAQ:ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced the appointment of Cintia Piccina, PharmD, MBA, as the company's Chief Commercial Officer, effective June 12, 2023. Ms. Piccina will drive the global commercialization strategy for AlloVir, with a focus on its lead product, posoleucel, and be responsible for building a commercial team in anticipation of a 2025 launch. "Cintia is an accomplished executive with a track record of successful cell therapy and oncology
5/16/23 7:00:00 AM ET
$ALVR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Top 4 Health Care Stocks That May Rocket Higher In Q1
The most oversold stocks in the health care presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here’s the latest list of major oversold players in this sector, having an RSI near or below 30. iBio, Inc. (NYSE:IBIO) On Dec. 5, iBio announced pricing of a $4.5 million public offering. The company’s stock fell around 11% over the
1/16/24 6:50:17 AM ET
$ALVR
$GRI
$IBIO
$VYNE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
On January 1, 2024, AlloVir Board Approved Reduction Its Workforce By Approximately 95% Of Current Employee Base To Reduce Costs And Preserve Capital - Filing
The move follows AlloVir’s announcement on December 22, 2023 that it is discontinuing its three global Phase 3 posoleucel studies. This workforce reduction will take place primarily during the first quarter of 2024 and expects to be substantially completed by April 15, 2024. As a result of these actions, AlloVir expects to incur personnel-related restructuring charges of approximately $13 million in connection with one-time employee termination cash expenditures, including severance and other benefits, which are expected to be substantially incurred in the first quarter of 2024.
1/4/24 5:27:25 PM ET
$ALVR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cognizant Technology Solutions To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. raised Karuna Therapeutics, Inc. (NASDAQ:KRTX) price target from $300 to $330. HC Wainwright & Co. analyst Raghuram Selvaraju downgraded the stock from Buy to Neutral. Karuna Therapeutics shares jumped 47.7% to close at $317.85 on Friday. See how other analysts view this stock. B of A Securities cut the price target for AlloVir, Inc. (NASDAQ:ALVR) from $17 to $1. B of A Securities analyst Jason Zemansky downgraded the stock from Buy to Underperform. AlloVir shares fell 67.2% to
12/26/23 8:03:37 AM ET
$ALVR
$CMS
$CTSH
$EQ
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Power Generation
Utilities

AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo
3/4/24 5:37:52 PM ET
$ALVR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio
2/28/24 1:06:25 AM ET
$ALVR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns identified Company to prioritize capital preservation and review strategic options AlloVir reported $213.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023 WALTHAM, Mass., Dec. 22, 2023 (GLOBE NEWSWIRE) -- AlloVir, Inc. (NASDAQ:ALVR), an allogeneic T cell immunotherapy company, today provided an update on its three Phase 3 clinical trials with posoleucel, an investigational off-the-shelf multi-virus-s
12/22/23 7:00:00 AM ET
$ALVR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

On January 1, 2024, AlloVir Board Approved Reduction Its Workforce By Approximately 95% Of Current Employee Base To Reduce Costs And Preserve Capital - Filing

Chat with this insight

Recent Analyst Ratings for
$ALVR

$ALVR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

General Counsel Miller Edward sold $1,965 worth of shares (2,272 units at $0.86), decreasing direct ownership by 1% to 211,931 units (SEC Form 4)

Chief Executive Officer Brainard Diana sold $9,176 worth of shares (10,609 units at $0.86), decreasing direct ownership by 1% to 732,069 units (SEC Form 4)

Chief Accounting Officer Hagen Brett R sold $1,431 worth of shares (1,655 units at $0.86), decreasing direct ownership by 2% to 69,060 units (SEC Form 4)

$ALVR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

AlloVir downgraded by BofA Securities with a new price target

AlloVir downgraded by Leerink Partners

AlloVir downgraded by JP Morgan

$ALVR
SEC Filings

SEC Form 425 filed by AlloVir Inc.

SEC Form 425 filed by AlloVir Inc.

SEC Form 425 filed by AlloVir Inc.

$ALVR
Leadership Updates

Live Leadership Updates

AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline

AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline

AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer

$ALVR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

$ALVR
Market Insights

Live Market Insights

$ALVR
Press Releases

Fastest customizable press release news feed in the world

SEC Form SC 13G filed by AlloVir Inc.

Amendment: SEC Form SC 13G/A filed by AlloVir Inc.

SEC Form SC 13G/A filed by AlloVir Inc. (Amendment)

Top 4 Health Care Stocks That May Rocket Higher In Q1